Unicharm (OTCMKTS:UNICY - Get Free Report) released its quarterly earnings results on Friday. The company reported $0.05 EPS for the quarter, Zacks reports. The business had revenue of $1.49 billion for the quarter, compared to analyst estimates of $1.69 billion. Unicharm had a return on equity of 10.24% and a net margin of 8.67%.
Unicharm Price Performance
OTCMKTS UNICY traded down $0.14 during trading hours on Friday, reaching $4.35. 296,518 shares of the company's stock were exchanged, compared to its average volume of 590,534. The stock has a market cap of $12.75 billion, a PE ratio of 21.75 and a beta of 0.35. Unicharm has a one year low of $3.48 and a one year high of $8.10. The firm has a fifty day moving average of $4.23 and a 200-day moving average of $4.50. The company has a current ratio of 2.22, a quick ratio of 1.79 and a debt-to-equity ratio of 0.01.
About Unicharm
(
Get Free Report)
Unicharm Corporation engages in the manufacturing and sale of wellness, feminine, baby and children, kirei, and pet care products in Japan and internationally. The company's baby and child care products, including disposable diapers and wipes under the Moony, MamyPoko, Oyasumiman, and Torepanman brands; feminine care products comprise napkins, tampons, panty liners, sanitary short, panty liners, and other feminine care products under the Sofy, Center-In, and Unicharm brand names; and wellness care products include napkin-type incontinence pads, pants-type diapers, tape-type diapers, pants-type specialized urine pads, and tape-type specialized urine pads under the Lifree and Charmnap brand.
Further Reading
Before you consider Unicharm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicharm wasn't on the list.
While Unicharm currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
